Pharma Dynamics (Pty) Ltd

pharmadynamics.co.za

Pharma Dynamics is the country’s leader in cardiovascular medication since 2012 - both in terms of value and volume – and is the fastest growing generic pharmaceutical company in South Africa. The organisation celebrates 16 years of improving the quality of life for South Africans after entrenching its mark in the industry with the launch of Amloc and Bilocor – SA’s two top selling anti-hypertensives. Today, Pharma Dynamics is active in more than 27 therapeutic areas, which include Central Nervous System (CNS), Female Healthcare, antimicrobial, pain and GIT categories, and it also supplies a range of Over the Counter (OTC) products.

Related News

PIRAMAL PHARMA SOLUTIONS TO ACQUIRE MANUFACTURING FACILITY OF G&W LABORATORIES IN US

livemint | June 20, 2020

news image

Piramal Enterprises Ltd's Pharma Solutions business, a contract development and manufacturing organization, on Saturday announced that it has entered into an agreement with G&W Laboratories Inc. to acquire its solid oral dosage drug product manufacturing facility located in Pennsylvania, USA, for $17.5 million. The all-cash deal is subject to customary pre-closing conditions. According to the terms of the agreement, Piramal Enterprises, through one of its affiliates, would acquire at clo...

Read More

ANDA APPROVES GLENMARK PHARMACEUTICALS FOR SIROLIMUS TABLETS, 0.5 MG, 1 MG AND 2 MG

Glenmark Pharmaceuticals Inc | October 19, 2020

news image

Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg, the generic version of Rapamune®1 Tablets, 0.5 mg, 1 mg and 2 mg, of PF Prism CV. According to IQVIATM sales data for the 12 month period ending August 2020, the Rapamune® Tablets, 0.5 mg, 1 mg and 2 mg market2 achieved annual sales of approximately $119.7 million*. Glenmark's current portfolio consists ...

Read More

NURO’S SELF-DRIVING VEHICLES TO DELIVER PRESCRIPTIONS FOR CVS PHARMACY

Techcrunch | May 28, 2020

news image

Nuro, the autonomous robotics startup that has raised more than $1 billion from SoftBank Vision Fund, Greylock and other investors, said Thursday it will test prescription delivery in Houston through a partnership with CVS Pharmacy. The pilot, which will use a fleet of the startup’s autonomous Toyota Prius vehicles and transition to using its custom-built R2 delivery bots, is slated to begin in June. The partnership marks Nuro’s expansion beyond groceries and into healthcare. L...

Read More

BUSINESS INSIGHTS

FUSION PHARMACEUTICALS AND NIOWAVE ANNOUNCE ACTINIUM-225 COLLABORATION AND SUPPLY AGREEMENT

Fusion Pharmaceuticals Inc. | June 13, 2022

news image

Fusion Pharmaceuticals Inc. a clinical-stage oncology company focused on developing next-generation radio pharmaceuticals as precision medicines, and Niowave, Inc., a manufacturer of medical radioisotopes from radium and uranium, today announced that the companies have entered into a collaboration and supply agreement for the development, production, and supply of actinium-225. Under the agreement, Fusion will invest up to $5 million in Niowave to further develop their technology to increase cur...

Read More
news image

PIRAMAL PHARMA SOLUTIONS TO ACQUIRE MANUFACTURING FACILITY OF G&W LABORATORIES IN US

livemint | June 20, 2020

Piramal Enterprises Ltd's Pharma Solutions business, a contract development and manufacturing organization, on Saturday announced that it has entered into an agreement with G&W Laboratories Inc. to acquire its solid oral dosage drug product manufacturing facility located in Pennsylvania, USA, for $17.5 million. The all-cash deal is subject to customary pre-closing conditions. According to the terms of the agreement, Piramal Enterprises, through one of its affiliates, would acquire at clo...

Read More
news image

ANDA APPROVES GLENMARK PHARMACEUTICALS FOR SIROLIMUS TABLETS, 0.5 MG, 1 MG AND 2 MG

Glenmark Pharmaceuticals Inc | October 19, 2020

Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg, the generic version of Rapamune®1 Tablets, 0.5 mg, 1 mg and 2 mg, of PF Prism CV. According to IQVIATM sales data for the 12 month period ending August 2020, the Rapamune® Tablets, 0.5 mg, 1 mg and 2 mg market2 achieved annual sales of approximately $119.7 million*. Glenmark's current portfolio consists ...

Read More
news image

NURO’S SELF-DRIVING VEHICLES TO DELIVER PRESCRIPTIONS FOR CVS PHARMACY

Techcrunch | May 28, 2020

Nuro, the autonomous robotics startup that has raised more than $1 billion from SoftBank Vision Fund, Greylock and other investors, said Thursday it will test prescription delivery in Houston through a partnership with CVS Pharmacy. The pilot, which will use a fleet of the startup’s autonomous Toyota Prius vehicles and transition to using its custom-built R2 delivery bots, is slated to begin in June. The partnership marks Nuro’s expansion beyond groceries and into healthcare. L...

Read More
news image

BUSINESS INSIGHTS

FUSION PHARMACEUTICALS AND NIOWAVE ANNOUNCE ACTINIUM-225 COLLABORATION AND SUPPLY AGREEMENT

Fusion Pharmaceuticals Inc. | June 13, 2022

Fusion Pharmaceuticals Inc. a clinical-stage oncology company focused on developing next-generation radio pharmaceuticals as precision medicines, and Niowave, Inc., a manufacturer of medical radioisotopes from radium and uranium, today announced that the companies have entered into a collaboration and supply agreement for the development, production, and supply of actinium-225. Under the agreement, Fusion will invest up to $5 million in Niowave to further develop their technology to increase cur...

Read More